Skip to main content

Table 1 Patients’ characteristics

From: Long-term sexual functioning in germ-cell tumor survivors

 

All (%)

Treatment group

 

AS

RT

CT

CTRT

P value

N = 170 (100%) (10)(((100)

     

Age (years)

 Median (range)

40 (21–77)

     

Follow up (years)

 Median (range)

9 (5–32)

     

Histology

 Pure seminoma

47 (28)

8

11

19

9

< 0.001

 Non-seminoma/mixed GCT

116 (68)

9

1

106

0

 

 Histology unknown

7 (4)

0

0

7

0

 

Primary tumor

 Gonadal

158 (92)

17

12

120

9

0.39

 Primary retroperitoneal

9 (6)

0

0

9

0

 

 Primary mediastinal

3 (2)

0

0

3

0

 

IGCCCG risk group

 Good risk

77 (49)

0

0

70

7

0.06

 Intermediate risk

21 (12)

0

0

21

1

 

 Poor risk

29 (17)

0

0

29

0

 

 unknown

1 (0.5)

0

0

1

0

 

Initial stage

 I

42 (26)

17

12

11

2

< 0.001

 I.S-III.A

77 (45)

0

0

70

7

 

 III.B

21 (11)

0

0

21

0

 

 III.C

29 (18)

0

0

29

0

 

 Stage unknown

 

0

0

1

0

 

Treatment

 AS

17 (10)

     

 RT only

12 (7)

     

  - adjuvant RT

12(7)

     

 CT only

132 (78)

     

  - 1st line only

112 (65)

     

  - more than 1st line

20(12)

     

 CTRT

9 (5)

     

  - 1st line treatment

8 (4.5)

     

  - 2nd line treatment

1 (0.5)b

     

Initial chemotherapy

 BEPx3

43 (26)

     

 EPx4

22 (13)

     

 BEPx4

43 (25)

     

 othera

33 (19)

     

Post-chemotherapy RPLND

 no

134

17

12

98

8

0.001

 yes

35

0

0

34

1

 

Time from the end of treatment (years)

 5–10

100 (59)

15

8

70

7

0.01

 11–15

41 (24)

1

4

35

1

 

 > 15

29 (17)

1

0

27

1

 
  1. aOther regimens included: adjuvant BEPx2 (N = 10), BEPx2 for stage I.S disease (N = 1), TBEPx4 (N = 6), TBEPx2 + EPx2 (N = 1), VAB VAI (N = 1), VIPx4 (N = 1), VIPx6 (N = 1), VIP × 4 + PVB × 1 (N = 1), BEPx2 + EPx2 (N = 1), high dose VIP (N = 3), TBEPx4 + TEPx1 (N = 1), GETUG 13 experimental arm (N = 2), PVB × 4 (N = 2), carboplatin + cyclophosphamide × 6 (N = 1)
  2. bpatient who had a relapse in CTRT group was initially treated with RT to the retroperitoneum and experienced systemic relapse 8 months later. He was treated with carboplatin + cyclophosphamide × 6. Subsequent relapse was treated with second line VIPx6
  3. Abbreviations: IGCCCG International Germ Cell Cancer Collaborative Group, NA Not available, AS Active surveillance, RT Radiotherapy, CT Chemotherapy, CTRT Chemotherapy and radiotherapy, RPLND Retroperitoneal lymph node dissection